Hepatitis B is a viral infection that causes inflammation and damage to the liver. Inflammation is the swelling that occurs when body tissues become injured or infected. Inflammation can damage organs. Chronic hepatitis B is a long-lasting infection. According to the National Institutes of Health (NIH), about 90 percent of children infected with hepatitis B develop a chronic infection. About 25-50% of infected children between the ages of 1 and 5 develop chronic infections. However, only about 5% of people first infected in adulthood develop chronic hepatitis B.

Increasing prevalence of hepatitis B and improved healthcare infrastructure are driving the growth in the size of the chronic hepatitis B market. For example, in April 2022, nearly 1 million people worldwide died of hepatitis B or hepatitis C each year, according to Bristol Myers & Squibb. Additionally, the increased awareness of hepatitis infection and advances in hepatitis treatment are driving the expansion of the chronic hepatitis B industry. 

The global Chronic Hepatitis B (CHB) Market size was estimated at $4.6 billion in 2021 and is expected to hit $6.1 billion by 2031, registering a CAGR of 3.0% from 2022 to 2031. The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/31973

Covid-19 scenario-

  • The outbreak of the pandemic had a negative impact on the global Chronic Hepatitis B (CHB) market. The outbreak of the pandemic in the majority of countries affected the supply chain and decreased blood donations across the world.
  • However, later on, several government initiatives to provide safer healthcare facilities and rise in blood donation rate for the treatment of Covid-19 with blood plasma helped the market recoup soon.

The global Chronic Hepatitis B (CHB) market is analyzed across Drug Class, Gender, Distribution Channel, and Region. The report takes in an exhaustive analysis of segments and their sub-segments with the help of tabular and graphical representation. Investors and market players can benefit from the breakdown and devise stratagems based on the highest revenue-generating and fastest-growing segments stated in the report.

Based on drug class, the antivirals segment contributed to 87% of the total market revenue in 2021, and is expected to dominate by 2031. The immune modulators segment, however, would manifest the fastest CAGR of 4.2% throughout the forecast period.

Speak to our Analyst :

By gender, the men’s segment accounted for more than half of the total market revenue in 2021 and is expected to dominate by 2031. The same segment would also cite the fastest CAGR of 3.2% over the entire forecast period. Based on the distribution channel, the drugstore and retail pharmacy segment accounted for nearly three-fifths of the total market revenue in 2021 and is expected to dominate by 2031. The Asia-Pacific region, at the same time, would show the higher CAGR. by 4.7% over the entire forecast period. Depending on the region, the North America market generated nearly two-fifths of the global market revenue in 2021 and is projected to retain the majority by 2031. The Asia-Pacific region would simultaneously record the fastest CAGR in the world. period. The other provinces analyzed in the report include Europe and LAMEA.

The key market players analyzed in the global Chronic Hepatitis B (CHB) market report include Dr. Reddy’s Laboratories,

Biocon Inc,



Gilead Sciences, Inc.,

Novartis AG,

Reliance Life Sciences,

Sun Pharmaceutical Industries Limited,

Teva pharmaceuticals,

Cipla Limited, and Viatris Inc. 

Leave a comment

Your email address will not be published. Required fields are marked *